Where Is Nano Today and Where Is It Headed? A Review of Nanomedicine and the Dilemma of Nanotoxicology | ACS Nano
![Breakthrough SARS-CoV-2 infections with the delta (B.1.617.2) variant in vaccinated patients with immune-mediated inflammatory diseases using immunosuppressants: a substudy of two prospective cohort studies - The Lancet Rheumatology Breakthrough SARS-CoV-2 infections with the delta (B.1.617.2) variant in vaccinated patients with immune-mediated inflammatory diseases using immunosuppressants: a substudy of two prospective cohort studies - The Lancet Rheumatology](https://www.thelancet.com/cms/attachment/9040e79a-8349-4e30-befc-5445cb337b88/gr1_lrg.gif)
Breakthrough SARS-CoV-2 infections with the delta (B.1.617.2) variant in vaccinated patients with immune-mediated inflammatory diseases using immunosuppressants: a substudy of two prospective cohort studies - The Lancet Rheumatology
![Landscape and perspectives of macrophage -targeted cancer therapy in clinical trials: Molecular Therapy - Oncolytics Landscape and perspectives of macrophage -targeted cancer therapy in clinical trials: Molecular Therapy - Oncolytics](https://www.cell.com/cms/attachment/f538bcc2-43ff-491b-ae24-fc7adaf6a1c9/gr1_lrg.jpg)